Janet Brutschea Haugen, a director at West Pharmaceutical Services Inc, has reported new stock transactions in a recent SEC filing. This filing, dated October 2, 2026, is significant as it showcases Haugen's ongoing involvement in the company's equity structure.
West Pharmaceutical Services Inc, which operates in the surgical and medical instruments industry, is known for its innovative solutions in the healthcare sector. The company is incorporated in Pennsylvania and has a fiscal year ending on December 31. It trades under the ticker symbol WST.
According to the filing, Haugen currently owns 2,114.18 shares of common stock following the recent transactions. Additionally, she reported acquiring 44 phantom stock units at a price of $370.76 per share on September 30, 2026. The filing notes that these phantom stock units will be settled by delivery of shares upon her termination as a director.
This update may affect shareholders and potential investors by providing insights into the actions of the company's directors. Such disclosures are essential for maintaining transparency and trust in corporate governance.
Details were not available in the SEC filing regarding any upcoming events or further actions related to these transactions.
Additional Insights from the SEC Filing
The SEC filing also highlights that Haugen's ownership of common stock includes 791 shares of restricted stock units, which are set to vest in full on the date of the next annual shareholder meeting. This vesting will allow for the distribution of these shares under the terms of the Deferred Compensation Plan for Outside Directors, indicating a structured approach to compensation for her role as a director.
Furthermore, the filing specifies that the phantom stock units acquired will be settled by the delivery of shares upon Haugen's termination as a director. This arrangement underscores the long-term incentive structure in place for directors at West Pharmaceutical Services Inc, aligning their interests with those of the shareholders.
It is noteworthy that the filing does not provide any information regarding Haugen's previous transactions or her overall investment strategy, leaving some gaps in understanding her complete financial engagement with the company.